Please assess the completion status of the following clinical trial:

Trial Title: Nutraceutical Efficacy for rUTI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For the RCT arms of the study, the following inclusion criteria will apply:~a. Postmenopausal women with recurrent UTI~i. Recurrent UTI defined as:~1. ≥ 2 symptomatic, culture-proven UTI in 6 months OR~2. ≥ 3 symptomatic, culture-proven UTI in 12 months~   ii. Postmenopausal defined as no menses for at least 12 months or surgical menopause~   b. At least one documented prior uropathogen susceptible to D-mannose~   c. Using VET for a minimum of four weeks prior to study day 1~   Inclusion criteria for the Observational arm of the study are the same with the exception of item 'c.' above (using VET for a minimum of four weeks) as participants will not be on vaginal estrogen therapy.~   Exclusion Criteria:~   For the RCT arms of the study, the exclusion criteria are as follows:~  1. Not postmenopausal~  2. Currently on daily antibiotic UTI prophylaxis (If this is the only exclusion criteria met, a woman could be cleared for inclusion in study/enrollment after a 2 week washout period occurs prior to inclusion in the study (RCT or Observational arm))~  3. Complicated UTIs (known renal tract anomaly, inability to empty bladder due to neurologic causes, performs self-catheterization or has an indwelling catheter)~  4. Patients with incomplete bladder emptying (defined as post void residual \> 150 cc when minimal voided volume is \>150 cc)~  5. Known contraindication to VET unless approved by patient's oncologist, oncologic surgeon, or primary care physician (History of or current endometrial cancer; History of estrogen sensitive breast cancer without approval of patient, patient's oncologist, oncologic surgeon, or primary care physician to use vaginal estrogen after counseling)~  6. History of interstitial cystitis/painful bladder syndrome~  7. Urothelial cancer~  8. Non-English speaking~  9. Enrolled in other clinical trials for UTIs~  10. Currently using D-mannose or Methenamine for UTI prevention~   Exclusion criteria for the Observational arm of the study are the same with the exception of item 'e.' above (known contraindication to VET) as participants will not be on vaginal estrogen therapy.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RCT treatment arm (Type: EXPERIMENTAL): Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
- RCT control arm (Type: NO_INTERVENTION): Participants in this arm will not use any additional intervention.
- Observational arm (Type: EXPERIMENTAL): Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy